MARY OTTEMAN: Open Payments
NPI 1821541905 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,999 in 86 payments from 19 companies in 2025. Trend: 2023 $1,945 · 2024 $1,704 · 2025 $1,999
Food & beverage: $1,838Education: $161
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 9 | $266 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 10 | $249 |
| Regeneron Healthcare Solutions, Inc. | 6 | $209 |
| Lilly USA, LLC | 9 | $196 |
| ABBVIE INC. | 10 | $172 |
| ConvaTec Inc. | 6 | $146 |
| GENZYME CORPORATION | 5 | $141 |
| Novartis Pharmaceuticals Corporation | 5 | $123 |
| UCB, Inc. | 6 | $112 |
| Galderma Laboratories, L.P. | 5 | $81 |
Products named: DUPIXENT, TREMFYA, ILUMYA, TALTZ, INNOVAMATRIX AC, SKYRIZI, COSENTYX, Bimzelx.
Industry payments across NE — which companies pay providers there.
